AWC, Ant Group Partner for Wide-ranging Initiatives to Enable Seamless Cross-border Payments for Consumers, Businesses
9.8.2023 05:00:00 EEST | Business Wire | Press release
Asset World Corp Public Company Limited or AWC, Thailand’s leading integrated lifestyle real estate group, and Ant Group, a global digital technology provider, have signed a memorandum of understanding (MoU) to launch various cross-border payment and digital financial solutions catered to the needs of AWC’s different businesses across hospitality, retail, wholesale and commercial, benefitting consumers, merchants and small businesses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230807578187/en/
Mrs. Wallapa Traisorat, AWC CEO and President, and Clara Shi, Vice President of Ant Group and Head of WorldFirst, signed the MoU in Bangkok (Photo: Business Wire)
Mrs. Wallapa Traisorat, AWC Chief Executive Officer and President, says, “With our vast and diverse real-estate portfolios in lifestyle hospitality, office buildings, Retail malls and wholesale centers in Thailand, AWC is strategically positioned to collaborate with industry-leading technology providers like Ant Group. Together, we can create seamless cross-border transaction experience for consumers and business operators globally, which can help drive the digital transformation of the real-estate industry in Thailand.”
One of the key initiatives under this collaboration is the implementation of WorldFirst cross-border business payment solutions for "PhenixBox," AWC's omnichannel online platform that processes trade activities from offline to online at its wholesale centers. By the end of 2023, AWC plans to enable local buyers, including SMEs, in Thailand to place orders and make payments in Thai Baht to global sellers, while enabling the sellers to collect payments in various major trade currencies.
WorldFirst, part of Ant Group, is a one-stop digital payments and financial services platform for SMEs engaged in cross-border trade. Through one World Account, WorldFirst customers will have the convenience of opening up to 14 local currency accounts online within minutes, enabling them to receive cross-border payments and manage funds from over 100 global marketplaces all through a single online portal. By partnering with 1688.com and other leading wholesale e-commerce platforms in China, WorldFirst is also the go-to payment channel for global merchants seeking a diverse range of cost-effective products from China.
Clara Shi, Vice President of Ant Group and Head of WorldFirst, says, “The partnership with AWC underscores the significance of effortless global payments for businesses, as it is the key to their success in today's interconnected world. By leveraging cutting-edge technology, Ant Group has created a comprehensive suite of cross-border payment solutions that removes barriers and streamlines cross-border transactions. We are committed to helping businesses confidently engage with partners, suppliers, and customers across borders through our omni-channel payment and financial services.”
Through Alipay+, AWC’s network of hospitality and retail businesses will be able to accept cross-border payments from leading Asian mobile wallets. This includes upscale hotels managed by leading global hotel chains and trendy malls such as Asiatique, in popular tourist destinations like Bangkok, Chiang Mai and Phuket. At these locations, international visitors can simply pay with their home local mobile wallets, eliminating the hassle of currency exchange and concerns about hidden fees.
Alipay+ is a suite of global cross-border digital payments and marketing solutions designed to enable businesses, especially small and medium-sized businesses, to process a wide range of mobile payment methods and reach 1 billion regional and global consumers, through one-time integration and simple technical adaption. Currently, four mobile wallets are accepted in Thailand through Alipay+, including Alipay from Chinese mainland, AlipayHK from Hong Kong SAR, Touch ‘n Go eWallet from Malaysia and Kakao Pay from South Korea.
2C2P, a full-suite payment platform provider and strategic partner of Ant Group, will support the partnership between AWC and Ant Group.
About Asset World Corp Public Company Limited
Asset World Corp Public Company Limited (AWC) is Thailand’s leading integrated lifestyle real estate group and a member of TCC Group, with the focus on hospitality, lifestyle destinations, and commercial workspaces. Driven by the philosophy of “Building a Better Future,” AWC strives to grow and expand beyond the norms with a diverse array of quality projects, providing responsible and sustainable solutions for all our stakeholders. The company has two main businesses. Hospitality business managed by top hotel executives of world-renowned hotel brands such as Marriott, The Luxury Collection, Okura, Banyan Tree, Hilton, Sheraton, and Melia, and Commercial properties whose projects include 1) Retail and Wholesale such as lifestyle travel destinations, community shopping malls, community markets, and wholesale business real estate. Popular real estate projects consist of Asiatique the Riverfront Destination, Gateway at Bangsue, AEC Trade Center – Pantip Wholesale Destination, and Tawanna Bangkapi, and 2) Commercial buildings including the famous ‘The Empire’ Tower and Athenee Tower located in Bangkok’s central business district. AWC is committed to integrating its sustainability strategy in every part of its operations to create long-term sustainable value for all stakeholders. The sustainability strategy consists of three key pillars: Better Planet, Better People and Better Prosperity, while the framework has created numerous long-term initiatives including the ReConcept, The GALLERY and other projects. For more information, please visit the company's website at www.assetworldcorp-th.com/en/home.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230807578187/en/
Contact information
AWC Media
Yuwadee Thavornchaisophon, Head of AWC Communications, yuwadee.t@assetworldcorp-th.com
Moke Promma, Corporate Communication Manager, moke.p@assetworldcorp-th.com
Partisar Poolthong, Corporate Communications Officer, partisar.p@assetworldcorp-th.com
Ant Group Media
Martin Mou, mouxu.mx@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom